Motolimod - CAS 926927-61-9
Catalog number:
926927-61-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C28H34N4O2
Molecular Weight:
458.6
COA:
Inquire
Targets:
Toll-like Receptor (TLR)
Description:
A small-molecule agonist of TLR8, with potential immunostimulating and antineoplastic activities
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
A small-molecule agonist of TLR8, with potential immunostimulating and antineoplastic activities
Appearance:
Solid powder
Synonyms:
VTX-2337; VTX-378; 2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide
Solubility:
10 mM in DMSO
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
InChIKey:
QSPOQCXMGPDIHI-UHFFFAOYSA-N
InChI:
1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
Canonical SMILES:
CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N
1.Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.
Dietsch GN1, Lu H2, Yang Y2, Morishima C2,3, Chow LQ4, Disis ML2, Hershberg RM1. PLoS One. 2016 Feb 29;11(2):e0148764. doi: 10.1371/journal.pone.0148764. eCollection 2016.
VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN). Activation of TLR8 enhances natural killer cell activation, increases antibody-dependent cell-mediated cytotoxicity, and induces Th1 polarizing cytokines. Here, we show that VTX-2337 stimulates the release of mature IL-1β and IL-18 from monocytic cells through coordinated actions on both TLR8 and the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome complex. In vitro, VTX-2337 primed monocytic cells to produce pro-IL-1β, pro-IL-18, and caspase-1, and also activated the NLRP3 inflammasome, thereby mediating the release of mature IL-1β family cytokines. Inhibition of caspase-1 blocked VTX-2337-mediated NLRP3 inflammasome activation, but had little impact on production of other TLR8-induced mediators such as TNFα.
2.VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Lu H1, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ, Disis ML, Hershberg RM. Clin Cancer Res. 2012 Jan 15;18(2):499-509. doi: 10.1158/1078-0432.CCR-11-1625. Epub 2011 Nov 29.
PURPOSE: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells.
3.A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
Northfelt DW1, Ramanathan RK2, Cohen PA1, Von Hoff DD3, Weiss GJ2, Dietsch GN4, Manjarrez KL4, Randall TD4, Hershberg RM5. Clin Cancer Res. 2014 Jul 15;20(14):3683-91. doi: 10.1158/1078-0432.CCR-14-0392. Epub 2014 May 7.
PURPOSE: This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacology of the TLR8 agonist VTX-2337 in subjects with advanced solid tumors or lymphoma.
4.Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
Dietsch GN1, Randall TD2, Gottardo R3, Northfelt DW4, Ramanathan RK5, Cohen PA4, Manjarrez KL2, Newkirk M2, Bryan JK2, Hershberg RM2. Clin Cancer Res. 2015 Dec 15;21(24):5445-52. doi: 10.1158/1078-0432.CCR-15-0578. Epub 2015 Jul 7.
PURPOSE: Immunotherapy as a treatment for cancer holds the promise of complete and durable tumor remission, yet the immunosuppressive environment created by many tumors, advanced patient age, and previous treatments with cytotoxic agents may limit the approach. The activity of motolimod (VTX-2337), a potent and selective Toll-like receptor 8 (TLR8) agonist, was therefore assessed in the context of advanced, late-stage cancer patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Toll-like Receptor (TLR) Products


RS 09
(CAS: 1449566-36-2)

TLR4 agonist

GardiquiMod
(CAS: 1020412-43-4)

A small-molecule agonist of TLR7

CAS 24936-38-7 Polyadenylic acid-Polyuridylic acid sodium salt

Polyadenylic acid-Polyuridylic acid sodi
(CAS: 24936-38-7)

TLR3 agonist

GS 9620
(CAS: 1228585-88-3)

A potent and oral agonist of TLR7

CAS 112208-00-1 Pam3CSK4

Pam3CSK4
(CAS: 112208-00-1)

TLR 1/2 agonist; A synthetic tripalmitoylated lipopeptide

CAS 926927-42-6 Toll-like receptor modulator

Toll-like receptor modulator
(CAS: 926927-42-6)

A TLR modulator

CU CPT 4a
(CAS: 1279713-77-7)

Selective TLR3 inhibitor(IC50 = 3.44 μM in RAW 264.7 cells)

CAS 926927-61-9 Motolimod

Motolimod
(CAS: 926927-61-9)

A small-molecule agonist of TLR8, with potential immunostimulating and antineoplastic activities

CAS 243984-11-4 TAK-242

TAK-242
(CAS: 243984-11-4)

A small-molecule-specific inhibitor of TLR4 signaling,

CPG52364 sulfate
(CAS: 1093135-62-6)

CPG52364 sulfate is the sulfate form of CPG52364, which is a small molecule toll-like receptor(TLR) antagonist. It has recently completed phase 1 clinical trial...

CAS 50-63-5 Chloroquine diphosphate

Chloroquine diphosphate
(CAS: 50-63-5)

Inhibits TLR signalling in plasmacytoid dendritic cells (pDCs)

CPG 7909

Agonist of TLR9; An immunomodulating synthetic oligonucleotide; As a monotherapy and in combination with chemotherapeutic agents, and also as an adjuvant for va...

CU CPT 22
(CAS: 1416324-85-0)

Selective TLR1/2 inhibitor(IC50 = 0.58 μM)

CAS 24939-03-5 Poly(I:C)

Poly(I:C)
(CAS: 24939-03-5)

TLR3 agonist; Made of one strand each of polyinosinic acid and polycytidylic acid

DSR 6434
(CAS: 1059070-10-8)

A potent TLR7 agonist (EC50 = 7.2 nM)

SM 324405
(CAS: 677773-91-0)

Potent TLR7 agonist (EC50 = 50 nM)

CL097
(CAS: 1026249-18-2)

Human TLR7/8 and mouse TLR7 agonist

CAS 6501-72-0 GIT 27

GIT 27
(CAS: 6501-72-0)

Interferes with TLR4, TLR2/6 signaling; Orally active immunomodulatory agent; Inhibits TNF-α secretion via interference of macrophage TLR4 and TLR 2/6 signaling...

TL8-506
(CAS: 1268163-15-0)

A benzoazepine compound, an agonist of TLR7, analog of the TLR8 agonist VTX-233

CAS 144875-48-9 Resiquimod

Resiquimod
(CAS: 144875-48-9)

An imidazoquinolinamine and TLR7 agonist with antitumor and antiviral activity; Phase I

Chemical Structure

CAS 926927-61-9 Motolimod

Quick Inquiry

Verification code

Featured Items